Your search for major depressive disorder returned 19 results

Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, improves excessive daytime sleepiness in OSA regardless of primary OSA therapy adherence.

Longitudinal changes in the dopamine transporter availability may identify patients with idiopathic REM sleep behavior disorder who are at risk of conversion to neurodegenerative diseases.

Researchers looked to further connect the dots between cognitive behavioral therapy for insomnia and repetitive negative thinking.

Exploring the risk of alcohol use disorders in patients with insomnia.

Examining the potential shared genetic liability of sleep deficits and cannabis use behaviors using multiple genomic methods.

Serotonergic antidepressants are effective for sleep disturbances in perimenopausal and postmenopausal women even without major depressive disorder.

Higher levels of outdoor artificial light at night are associated with less favorable sleep patterns as well as mood and anxiety disorders in adolescents.

Heightened cognitive arousal at bedtime is linked to objective sleep disturbances and indicators of psychological hyperarousal at night and during the day.

While insomnia medication efficacy has been studied in meta-analyses, this efficacy has largely been focused on study endpoints rather than time-course responses.

Digital CBT involved 6 weekly remote sessions via website or iOS app lasting approximately 20 minutes and comprised sleep restriction, stimulus control, relaxation techniques, cognitive therapy, and sleep hygiene and education.

The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.

The FDA has approved Somryst™ (Pear Therapeutics), a prescription digital therapeutic (PDT) intended for the treatment of patients 22 years of age and older with chronic insomnia.

Depression contributed to elevated ratings in patients with MDD on items related to perceived inability to cope with the negative consequences of disturbed sleep and reported tendency to cancel social plans after poor sleep.

Overall, in all patients with MDD, sleep ultradian cycle number was positively associated with REMS percentage, REMS duration, and REMS/NREMS ratio and negatively associated with REM latency.

There is an emerging view that sleep disorders are not merely symptoms of psychiatric conditions; instead there may be a complex, bidirectional relationship between psychiatric and sleep disorders.

In boys but not girls, reduced sleep duration at age 8 and 10 years predicted the development of behavioral disorder symptoms 2 years later.

Anna S. Urrila, MD and colleagues sought to explore whether sleep symptoms in adolescents with MDD were associated with long-term outcomes.

Common comorbidities in OSA such as cardiovascular disease and metabolic abnormalities, may confer a higher risk for the development of mental and cognitive impairment in patients with OSA compared with the general population.

Overall, 26 of the 34 studies suggested a positive relationship between insomnia and depression.